Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226453 · ClinicalTrials.gov registry record · Phase 2
Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma
A Phase 2 study of Posterior Fossa Ependymal Tumor, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07226453 is a Phase 2 study of Posterior Fossa Ependymal Tumor that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07226453, a Phase 2 study of Posterior Fossa Ependymal Tumor, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multi-site study of the pharmacodynamic effects and efficacy of metformin in children and young adults with recurrent or progressive Posterior Fossa Group A (PFA) ependymoma.
Conditions Studied
Interventions
- DRUG Metformin
- PROCEDURE Magnetic Resonance Imaging (MRI)
- PROCEDURE Specimen Collection
- PROCEDURE Planned Surgical Resection
- PROCEDURE MR spectroscopy (MRS)
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-03-04 |
| Est. Completion | 2030-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07226453
The ClinicalTrials.gov registry entry for NCT07226453 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Posterior Fossa Ependymal Tumor appearing as the primary indexed condition, and to 5 interventions - of which Metformin is the first listed.
NCT07226453 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07226453 about?
NCT07226453 is a clinical study titled "Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma". This is a multi-site study of the pharmacodynamic effects and efficacy of metformin in children and young adults with recurrent or progressive Posterior Fossa Group A (PFA) ependymoma.
What is the current status of trial NCT07226453?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-03-04. Estimated completion is 2030-03-31.
What conditions does trial NCT07226453 study?
This clinical trial studies the following conditions: Posterior Fossa Ependymal Tumor.
What interventions are being tested in trial NCT07226453?
The interventions under investigation include: Metformin (DRUG), Magnetic Resonance Imaging (MRI) (PROCEDURE), Specimen Collection (PROCEDURE), Planned Surgical Resection (PROCEDURE), MR spectroscopy (MRS) (PROCEDURE).
Who is sponsoring clinical trial NCT07226453?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226453 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.